Table 3.
Genotype Category | No. Evaluable at Baseline | Median Endoxifen Baseline* (ng/mL) | No. Completing Protocol-Driven Therapy | Median Endoxifen Baseline (ng/mL) | Median Endoxifen 4 Months Later† (ng/mL) | Intrapatient Change From Baseline (ng/mL) |
P‡ | |
---|---|---|---|---|---|---|---|---|
Median | Interquartile Range | |||||||
EM | 32 | 34.9 | 29 | 34.3 | 29.2 | −1.5 | −28 to 11.2 | .25 |
IM | 74 | 19.8 | 51 | 18.5 | 21.8 | +7.6 | −0.6 to 23.9 | < .001 |
PM | 11 | 4.6 | 9 | 4.2 | 12.9 | +6.1 | 2.6 to 12.5 | .020 |
Abbreviations: EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer.
Medians of the three groups are significantly different from each other with EM v IM: P = .0054; EM v PM: P < .001; IM v PM: P < .001.
Represents aggregate data within genotype groups, not intrapatient data.
Relates to the median intrapatient change from baseline.